CA2306985A1 - Novel use of compounds for anti-pruritic activity - Google Patents
Novel use of compounds for anti-pruritic activity Download PDFInfo
- Publication number
- CA2306985A1 CA2306985A1 CA002306985A CA2306985A CA2306985A1 CA 2306985 A1 CA2306985 A1 CA 2306985A1 CA 002306985 A CA002306985 A CA 002306985A CA 2306985 A CA2306985 A CA 2306985A CA 2306985 A1 CA2306985 A1 CA 2306985A1
- Authority
- CA
- Canada
- Prior art keywords
- xanthine
- compound
- cyclopropylmethyl
- butyl
- nitro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Abstract
Derivatives of 8-substituted xanthines which are used in the prophylactic or therapy of diseases or disorders which have a pruritic component.
Description
NOVEL USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY
FIELD OF INVENTION
The present invention relates to compounds which are of use in the treatment and management of pruritis.
BACKGROUND OF THE INVENTION
Pruritis is a common symptom of many inflammatory skin diseases, notably psoriasis and atopic dermatitis. This symptom has historically been dii~cult to model.
Recently, a behavioral model for peripherally evoked itch was published (Woodward et al., Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen. J. Pharmacol. Exp. Therap.
272:758-765, 1995). This model has lead to additional modifications as will be shown herein.
As little effective treatment for this condition exists, there remains a need for treatment, in this field, for compounds which are capable of anti-pruritic activity.
~UIvINIARY OF THE INVENTION
This invention relates to the novel use of PDE4 inhibitors, preferably compounds of Formula (I) for the prophylaxis, treatment and management of pruritis in a mammal, including humans, in need of such treatment, which method comprises administering to such mammal, an effective amount of a compound of Formula (I).
The compounds of the present invention of Formula (I) are described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure I demonstrates the anti-pruritic activity of compound I, l ,3-di-cyclopropylmethyl-8-amino xanthine in an arachidonic acid induced pruritis model.
DETAILED DESCRIPTION OF THE INVENTION
The present invention has found that PDE4 inhibitors, as a class of compounds, regardless of structure possess anti-pruritis activity As pruritis is a key symptom of many different disease states, the use of PDE4 inhibitors in the ~managment of praritic activity is of great value.
While it is recognized that PDE4 compounds are of many different structural classes, they all share a common feature, inhibition of the PDE4 isoenzymes. A
SUBSTITUTE SHEET (RULE 28) . skilled artisan, using well known and defined assays, will be able to determine if a compound is an inhibitor of the PDE4 isoenzymes, and be of use herein.
Suitable PDE4 compounds for use herein include, but are not limited to, those described in WO 92/00968; PCT/US91/08229; WO 92/05175; WO 92/05176; WO 92/11260;
WO 93/01014; PCT/US92/03613; WO 93/07111; PCT/CTS93/02045; WO
93/19748; WO 93/19750; WO 93/19751; WO 93/19747; WO 93/19749; WO
93/19720; WO 94/20079; WO 95/00139; WO 95/08581; WO 95/09308; WO
95/09623; WO 95/09836; WO 95/09624; WO 95/09837; WO 95/09627; WO
95/24381; WO 95/27692; WO 96/19995; WO 96/20158; WO 96/20153; WO
96/19980; WO 96/19988; W096/19977; WO 96/20161; WO 96/20157;
PCT/US95/i6707; WO 96/20690; WO 96/20159; WO 96/19983; WO
96/19984; WO 96/19985; WO 96/19990; WO 96/19994; WO 96/20163; WO
96/20156; WO 96/19986; WO 96/20174; WO 96/19979; WO 96/20160 WO
96/20175; WO 96/19993; WO 96/20162; WO 96/19978; WO 96/23754; WO
96/36594; ; WO 97/03945, US 5,734,051 and US 5,420,154. Suitable assays for determination of PDE4 activity are also described in the above noted references, whose disclosures are incorporated by reference herein in their entirety.
A particular PDE4, CP 80633 is described in J.M. Hanifin et al. J. Invest.
De~~~~atol. 107:51-56 (1996). Preferably, the method of use does net include the compound CP80633.
The compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than in humans, in need of such treatment for pruritis. Treatment. may be therapeutically or prophylactically in animals .
The compounds of the present invention of Formula (I), are described in US
Patent 5,734,051 and are represented by the structure:
R~~ H
N N
~--Rs I
R 2 lIl wherein R1 and R~ are each independently alkyl or a moiety of the formula -(CHZ)m-A;
m is a number from 0 to 3;
A is an unsubstituted or substituted cyclic hydrocarbon radical;
SUBSTITUTE SHEET (RULE 26) R3 is halogen, vitro, or -NRqRs;
R4 and RS are independently hydrogen, alkyl, alkylcarbonyl or together with the nitrogen to which they are attached forming an optionally substituted heterocyclic ring; and the pharmaceutically acceptable salts thereof.
Preferably both Rl and R2 represent -(CHZ)n,-A. Preferably the A moiety represents a C3_g cycloalkyl group, particularly a C3~ cycloalkyl and preferably unsubstituted. More preferably A is a cyclopropyl or cyclobutyl moiety.
Preferably m is zero or one. Suitable optional substituent groups for any cyclic hydrocarbon include a Ci~alkyl moiety or halogen atom.
A preferred group for Rl or R2 is an alkyl group of 1 to 6 carbons, specifically methyl, ethyl, propyl or n-butyl. More preferred is n-butyl.
When R3 is halogen, the preferred substitution is bromine or chlorine.
When R3 is -NR4R5, and R4 and RS represent alkyl or alkylcarbonyl, it is l 5 preferred that one of R4 or RS is hydrogen.
Suitable heterocyclic groups include saturated or unsaturated heterocylic groups having single or firsed rings, each ring having 5 to 7 ring atoms which ring atoms optionally comprise up to two additional hetero atoms selected from O, N, or S.
Preferred heterocyclic groups include single rings comprising 5 to 7 ring atoms, more preferably 5 to 6 ring atoms,and most preferably 6 ring atoms.
Preferred heterocyclic groups are pyrrolidinyl, piperidinyl, or morpholinyl rings.
Specifically exemplified compounds of Formula (I) are:
1,3-di-n-butyl-8-vitro xanthine;
1,3-di-cyclopropylmethyl-8-vitro xanthine;
1,3-di-cyclobutylmethyl-8-vitro xanthine;
1,3-di-cyclopentylmethyl-8-vitro xanthine;
1,3-di-cyclohexylmethyl-8-vitro xanthine;
1,3-di-n-butyl-8-amino xanthine;
1,3-di-cyclopropyimethyl-8-amino xanthine;
1,3-di-cyclobutylmethyl-8-amino xanthine;
1,3-di-cyclopentylmethyl-8-amino xanthine;
1,3-di-cyclohexylmethyl-8-amino xanthine;
1,3-di-cyclopropyl-8-amino xanthine;
1,3-di-n-butyl-8-acetamido xanthine;
_,_ SUBSTITUTE SHEET (RULE 26) 1,3-di-n-butyl-8-chloro xanthine;
1,3-di-n-butyl-8-bromo xanthine;
1,3-di-cyclopropylmethyl-8-chloro xanthine;
1,3-di-cyclohexyl-8-chloro xanthine;
1,3-di-n-butyl-8-piperidino xanthine;
1,3-di-cyclopropylmethyl-8-morpholino xanthine;
1,3-di-n-butyl-8-pyrrolidinyl xanthine;
1,3-di-cyclopropylmethyl-8-pyrrolidinyl xanthine;
1,3-di-cyclopropylmethyl-8-piperidinyl xanthine;
1,3-di-cyclohexylmethyl-8-piperidinyl xanthine;
1,3-di-cyclohexylmethyl-8-bromo xanthine; and 1,3-di-cyclohexyl-8-vitro xanthine; or the pharmaceutically acceptable salts thereof.
The most preferred compound of Formula (I) for use in the method of this invention is 1,3-di-cyclopropylmethyl-8-amino xanthine or a pharmaceutically acceptable salt thereof.
By the term "alkyl" groups as used herein, alone or when used as part of another group (for example as in alkylcarbonyl) is meant to include both straight or branched chain radicals of 1 to 12 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.
By the term "cyclic hydrocarbon", unless specified otherwise, as used herein is meant a single ring or a fused rings of 3 to 8 carbon atoms. Cyclic hydrocarbons may comprise up to 8 carbons in each ring. The term "cycloalkyl" or "cycloalkyl alkyl" as used herein is meant to be interchangeable with the term "cyclic hydrocarbon".
Cycloalkyl and cycloalkyl-alkyl groups are meant to include, but not limited to cyclopropyl, cyclopropyl-methyl, cyciopentyl or cyclohexyl.
By the term "halo" as used herein is meant all halogens, i.e., chloro, fluoro, bromo and iodo.
METHODS OF PREPARATION
The preparation of the compounds of Formula (I) can be carried out by one of skill in the art according to the procedures outlined herein, and as described in Maschler et al., Great Britain Patent Application No. 8906792.0 filed on March 23, _ ,I _ SUBSTITUTE SHEET (RULE 26) 1989, and US Patent No. 5,734,051 whose entire disclosures are incorporated herein by reference in its entirety.
METHODS OF TREATMENT
The compounds of Formula (I) or a pharmaceutically acceptable salt thereof can_ also be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or or unregulated pruritic activity.
The compounds of Formula (I) rnay be used topically in the treatment or prophylaxis of topical disease states which have a pruritic component.
The compounds of Formula (I) are disclosed in Maschler et al., Great Britain Patent Application No. 8906792.0 filed on March 23, 1989, and US Patent 5,734,051 for the treatment of disorders associated with increased numbers of eosinophils, such as proliferative skin disease states, i.e. psoriasis, atopic dermatitis, non-specific dermatitis, I 5 primary irritant contact dermatitis, allergic contact dermatitis, or allergic disorders such as atopy, uticaria, eczema, rhinitis, serb~rrheic dermatitis, and mange in domestic animals. The compounds of Formula (I) are also disclosed in PCT/LJS91/08734, and PCT/US93/01496 published as WO 93/06699 whose dislosures are incorporated herein by reference in its entirety, for the treatment of tumour necrosis n-~edaated diseases.
The compounds of Formula (I) may, be administered concurrently with another agents useful for the treatment or managment of pruritis, such as steroids.
It will be recognized by one of skill in the art that the actual amount of a monokine activity interfering agent required for therapeutic effect will, of course, vary with the agent chosen, the route of administration desired, the nature and severity of the disease, and the particular condition of the mammal, specifically human, undergoing treatment, and is ultimately at the discretion of the physician. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of the agent will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the agent given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
The compounds of Formula (I) may be administered orally (when active by this route), topically, parenterally or by inhalation in conventional dosage forms SUBSTITUTE SHEET (RULE 26) prepared by combining such agent with standard pharmaceutical carriers according to conventional procedures in an amount sufficient to produce therapeutic activity.
The pharmaceutical carrier employed can be readily determined by one of skill in the art who will recognize that such determination will depend upon various well-s known factors such as the nature, quantity and character of the particular monokine activity interfering agent being employed and the form and route of administration desired. The carriers employed may be those described elsewhere herein.
In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
The pharmaceutical composition of the present invention will comprise an effective, non-toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent. The compounds of Formula (I) are administered in conventional dosage forms prepared by combining a compound of Formula (I) in an amount sufficient to produce activity, respectively, with standard pharmaceutical carriers according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra albs, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, polyethylene glycol, coconut oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
Compounds of Formula {I) and their pharmaceutically acceptable salts can be employed in a wide variety of pharmaceutical forms. The preparation of a pharmaceutically acceptable salt will be determined by the nature of the compound itself, and can be prepared by conventional techniques readily available to one skilled 3U in the art. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
The amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1 gram. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a SUBSTITUTE SHEET (RULE 26) . hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, polyethylene glycol, coconut oil, glycerine or water with a flavouring or colouring agent.
The amount of a compound of Formula (I) required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the inflammatory condition and the animal undergoing treatment, and is ultimately at the discretion of the physician.
The term'parenteral' as used herein includes intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration.
The subcutaneous and intramuscular forms of parenteral administration are generailv preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques.
Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a pareater«lly acceptable oil, for example polyethylene glycol, polyvinylpynolidonc, lecithin, arachis oil, or sesame oil. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, preferably about 0.01 mg/Kg to 20 mg/Kg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
The compounds of Formula (I) may be administered orally. The daily dosage regimen for oral administration is suitably about .1 mg/kg to 1000mg day. For administration the dosage is suitably about .OOlmg/kg to 40mg/kg, preferably about 0.01 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base. The active ingredient may be administered from 1 to 6 times a day, su~cient to exhibit activity.
The compounds of Formula (I) may also be administered by inhalation. By "inhalation" is meant intranasal and oral inhalation administration.
Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. The daily dosage regimen for inhalation administration is suitably about .001 mg/kg to 40mg/kg, preferably 0.01 3 S to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
SUBSTITUTE SHEET (RULE 26) . Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose.
The compounds of Formula (I) may also be administered topically. By topica.l administration is meant non-systemic administration and includes the application of a compound of Formula (I) externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the I O compound does not significantly enter the blood stream. The daily dosage regimen for topical administration is suitably about .001 mg/kg to 100mg/kg, preferably 0.1 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
By systemic administration is meant oral, intravenous, intraperitoneal and I S intramuscular administration.
While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g.
from 1% to 2°o by weight ofthe formulation although it may comprise as mach as 20 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1 % to 1 % w/w of the formulation.
The topical formulations of the present invention comprise an active ingredient together with one or more acceptable carriers) therefor and optionally any other therapeutic ingredient(s). The carriers) must be'acceptable' in the sense of being 25 compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to 30 the eye, ear or nose.
Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting 35 solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100~C for half an hour.
_g_ SUBSTITUTE SHEET (RULE 26) Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. Thev may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage;
an oil of natural origin such as almond, corn, arachis, castor or olive ail; wool fat o.
its derivatives, or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or macrogols. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactants such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums. cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient, a compound of Formula (I), with which it is to be combined, the route of administration and other well-known variables.
It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration. and the particular patient being treated, and that such optimums can be determined by conventional techniques.
It will also be appreciated by one of skill in the art that the optimal course of treatment. i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable _g_ SUBSTITUTE SHEET (RULE 26) salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
FORMULATION EXAMPLES
Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients.
Examples .
of liquid formulations are given below.
1. A solution containing a compound of Formula (I) is prepared by dissolving the compound in water, or other suitable earner, with or without a preservative, such as benzoic acid, to deliver the desired amount of drug per use. The compound is present in an amount from about 10~g to about 30 fig/ per ml of carrier.
FIELD OF INVENTION
The present invention relates to compounds which are of use in the treatment and management of pruritis.
BACKGROUND OF THE INVENTION
Pruritis is a common symptom of many inflammatory skin diseases, notably psoriasis and atopic dermatitis. This symptom has historically been dii~cult to model.
Recently, a behavioral model for peripherally evoked itch was published (Woodward et al., Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen. J. Pharmacol. Exp. Therap.
272:758-765, 1995). This model has lead to additional modifications as will be shown herein.
As little effective treatment for this condition exists, there remains a need for treatment, in this field, for compounds which are capable of anti-pruritic activity.
~UIvINIARY OF THE INVENTION
This invention relates to the novel use of PDE4 inhibitors, preferably compounds of Formula (I) for the prophylaxis, treatment and management of pruritis in a mammal, including humans, in need of such treatment, which method comprises administering to such mammal, an effective amount of a compound of Formula (I).
The compounds of the present invention of Formula (I) are described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure I demonstrates the anti-pruritic activity of compound I, l ,3-di-cyclopropylmethyl-8-amino xanthine in an arachidonic acid induced pruritis model.
DETAILED DESCRIPTION OF THE INVENTION
The present invention has found that PDE4 inhibitors, as a class of compounds, regardless of structure possess anti-pruritis activity As pruritis is a key symptom of many different disease states, the use of PDE4 inhibitors in the ~managment of praritic activity is of great value.
While it is recognized that PDE4 compounds are of many different structural classes, they all share a common feature, inhibition of the PDE4 isoenzymes. A
SUBSTITUTE SHEET (RULE 28) . skilled artisan, using well known and defined assays, will be able to determine if a compound is an inhibitor of the PDE4 isoenzymes, and be of use herein.
Suitable PDE4 compounds for use herein include, but are not limited to, those described in WO 92/00968; PCT/US91/08229; WO 92/05175; WO 92/05176; WO 92/11260;
WO 93/01014; PCT/US92/03613; WO 93/07111; PCT/CTS93/02045; WO
93/19748; WO 93/19750; WO 93/19751; WO 93/19747; WO 93/19749; WO
93/19720; WO 94/20079; WO 95/00139; WO 95/08581; WO 95/09308; WO
95/09623; WO 95/09836; WO 95/09624; WO 95/09837; WO 95/09627; WO
95/24381; WO 95/27692; WO 96/19995; WO 96/20158; WO 96/20153; WO
96/19980; WO 96/19988; W096/19977; WO 96/20161; WO 96/20157;
PCT/US95/i6707; WO 96/20690; WO 96/20159; WO 96/19983; WO
96/19984; WO 96/19985; WO 96/19990; WO 96/19994; WO 96/20163; WO
96/20156; WO 96/19986; WO 96/20174; WO 96/19979; WO 96/20160 WO
96/20175; WO 96/19993; WO 96/20162; WO 96/19978; WO 96/23754; WO
96/36594; ; WO 97/03945, US 5,734,051 and US 5,420,154. Suitable assays for determination of PDE4 activity are also described in the above noted references, whose disclosures are incorporated by reference herein in their entirety.
A particular PDE4, CP 80633 is described in J.M. Hanifin et al. J. Invest.
De~~~~atol. 107:51-56 (1996). Preferably, the method of use does net include the compound CP80633.
The compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than in humans, in need of such treatment for pruritis. Treatment. may be therapeutically or prophylactically in animals .
The compounds of the present invention of Formula (I), are described in US
Patent 5,734,051 and are represented by the structure:
R~~ H
N N
~--Rs I
R 2 lIl wherein R1 and R~ are each independently alkyl or a moiety of the formula -(CHZ)m-A;
m is a number from 0 to 3;
A is an unsubstituted or substituted cyclic hydrocarbon radical;
SUBSTITUTE SHEET (RULE 26) R3 is halogen, vitro, or -NRqRs;
R4 and RS are independently hydrogen, alkyl, alkylcarbonyl or together with the nitrogen to which they are attached forming an optionally substituted heterocyclic ring; and the pharmaceutically acceptable salts thereof.
Preferably both Rl and R2 represent -(CHZ)n,-A. Preferably the A moiety represents a C3_g cycloalkyl group, particularly a C3~ cycloalkyl and preferably unsubstituted. More preferably A is a cyclopropyl or cyclobutyl moiety.
Preferably m is zero or one. Suitable optional substituent groups for any cyclic hydrocarbon include a Ci~alkyl moiety or halogen atom.
A preferred group for Rl or R2 is an alkyl group of 1 to 6 carbons, specifically methyl, ethyl, propyl or n-butyl. More preferred is n-butyl.
When R3 is halogen, the preferred substitution is bromine or chlorine.
When R3 is -NR4R5, and R4 and RS represent alkyl or alkylcarbonyl, it is l 5 preferred that one of R4 or RS is hydrogen.
Suitable heterocyclic groups include saturated or unsaturated heterocylic groups having single or firsed rings, each ring having 5 to 7 ring atoms which ring atoms optionally comprise up to two additional hetero atoms selected from O, N, or S.
Preferred heterocyclic groups include single rings comprising 5 to 7 ring atoms, more preferably 5 to 6 ring atoms,and most preferably 6 ring atoms.
Preferred heterocyclic groups are pyrrolidinyl, piperidinyl, or morpholinyl rings.
Specifically exemplified compounds of Formula (I) are:
1,3-di-n-butyl-8-vitro xanthine;
1,3-di-cyclopropylmethyl-8-vitro xanthine;
1,3-di-cyclobutylmethyl-8-vitro xanthine;
1,3-di-cyclopentylmethyl-8-vitro xanthine;
1,3-di-cyclohexylmethyl-8-vitro xanthine;
1,3-di-n-butyl-8-amino xanthine;
1,3-di-cyclopropyimethyl-8-amino xanthine;
1,3-di-cyclobutylmethyl-8-amino xanthine;
1,3-di-cyclopentylmethyl-8-amino xanthine;
1,3-di-cyclohexylmethyl-8-amino xanthine;
1,3-di-cyclopropyl-8-amino xanthine;
1,3-di-n-butyl-8-acetamido xanthine;
_,_ SUBSTITUTE SHEET (RULE 26) 1,3-di-n-butyl-8-chloro xanthine;
1,3-di-n-butyl-8-bromo xanthine;
1,3-di-cyclopropylmethyl-8-chloro xanthine;
1,3-di-cyclohexyl-8-chloro xanthine;
1,3-di-n-butyl-8-piperidino xanthine;
1,3-di-cyclopropylmethyl-8-morpholino xanthine;
1,3-di-n-butyl-8-pyrrolidinyl xanthine;
1,3-di-cyclopropylmethyl-8-pyrrolidinyl xanthine;
1,3-di-cyclopropylmethyl-8-piperidinyl xanthine;
1,3-di-cyclohexylmethyl-8-piperidinyl xanthine;
1,3-di-cyclohexylmethyl-8-bromo xanthine; and 1,3-di-cyclohexyl-8-vitro xanthine; or the pharmaceutically acceptable salts thereof.
The most preferred compound of Formula (I) for use in the method of this invention is 1,3-di-cyclopropylmethyl-8-amino xanthine or a pharmaceutically acceptable salt thereof.
By the term "alkyl" groups as used herein, alone or when used as part of another group (for example as in alkylcarbonyl) is meant to include both straight or branched chain radicals of 1 to 12 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.
By the term "cyclic hydrocarbon", unless specified otherwise, as used herein is meant a single ring or a fused rings of 3 to 8 carbon atoms. Cyclic hydrocarbons may comprise up to 8 carbons in each ring. The term "cycloalkyl" or "cycloalkyl alkyl" as used herein is meant to be interchangeable with the term "cyclic hydrocarbon".
Cycloalkyl and cycloalkyl-alkyl groups are meant to include, but not limited to cyclopropyl, cyclopropyl-methyl, cyciopentyl or cyclohexyl.
By the term "halo" as used herein is meant all halogens, i.e., chloro, fluoro, bromo and iodo.
METHODS OF PREPARATION
The preparation of the compounds of Formula (I) can be carried out by one of skill in the art according to the procedures outlined herein, and as described in Maschler et al., Great Britain Patent Application No. 8906792.0 filed on March 23, _ ,I _ SUBSTITUTE SHEET (RULE 26) 1989, and US Patent No. 5,734,051 whose entire disclosures are incorporated herein by reference in its entirety.
METHODS OF TREATMENT
The compounds of Formula (I) or a pharmaceutically acceptable salt thereof can_ also be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or or unregulated pruritic activity.
The compounds of Formula (I) rnay be used topically in the treatment or prophylaxis of topical disease states which have a pruritic component.
The compounds of Formula (I) are disclosed in Maschler et al., Great Britain Patent Application No. 8906792.0 filed on March 23, 1989, and US Patent 5,734,051 for the treatment of disorders associated with increased numbers of eosinophils, such as proliferative skin disease states, i.e. psoriasis, atopic dermatitis, non-specific dermatitis, I 5 primary irritant contact dermatitis, allergic contact dermatitis, or allergic disorders such as atopy, uticaria, eczema, rhinitis, serb~rrheic dermatitis, and mange in domestic animals. The compounds of Formula (I) are also disclosed in PCT/LJS91/08734, and PCT/US93/01496 published as WO 93/06699 whose dislosures are incorporated herein by reference in its entirety, for the treatment of tumour necrosis n-~edaated diseases.
The compounds of Formula (I) may, be administered concurrently with another agents useful for the treatment or managment of pruritis, such as steroids.
It will be recognized by one of skill in the art that the actual amount of a monokine activity interfering agent required for therapeutic effect will, of course, vary with the agent chosen, the route of administration desired, the nature and severity of the disease, and the particular condition of the mammal, specifically human, undergoing treatment, and is ultimately at the discretion of the physician. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of the agent will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the agent given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
The compounds of Formula (I) may be administered orally (when active by this route), topically, parenterally or by inhalation in conventional dosage forms SUBSTITUTE SHEET (RULE 26) prepared by combining such agent with standard pharmaceutical carriers according to conventional procedures in an amount sufficient to produce therapeutic activity.
The pharmaceutical carrier employed can be readily determined by one of skill in the art who will recognize that such determination will depend upon various well-s known factors such as the nature, quantity and character of the particular monokine activity interfering agent being employed and the form and route of administration desired. The carriers employed may be those described elsewhere herein.
In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
The pharmaceutical composition of the present invention will comprise an effective, non-toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent. The compounds of Formula (I) are administered in conventional dosage forms prepared by combining a compound of Formula (I) in an amount sufficient to produce activity, respectively, with standard pharmaceutical carriers according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra albs, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, polyethylene glycol, coconut oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
Compounds of Formula {I) and their pharmaceutically acceptable salts can be employed in a wide variety of pharmaceutical forms. The preparation of a pharmaceutically acceptable salt will be determined by the nature of the compound itself, and can be prepared by conventional techniques readily available to one skilled 3U in the art. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
The amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1 gram. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a SUBSTITUTE SHEET (RULE 26) . hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, polyethylene glycol, coconut oil, glycerine or water with a flavouring or colouring agent.
The amount of a compound of Formula (I) required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the inflammatory condition and the animal undergoing treatment, and is ultimately at the discretion of the physician.
The term'parenteral' as used herein includes intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration.
The subcutaneous and intramuscular forms of parenteral administration are generailv preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques.
Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a pareater«lly acceptable oil, for example polyethylene glycol, polyvinylpynolidonc, lecithin, arachis oil, or sesame oil. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, preferably about 0.01 mg/Kg to 20 mg/Kg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
The compounds of Formula (I) may be administered orally. The daily dosage regimen for oral administration is suitably about .1 mg/kg to 1000mg day. For administration the dosage is suitably about .OOlmg/kg to 40mg/kg, preferably about 0.01 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base. The active ingredient may be administered from 1 to 6 times a day, su~cient to exhibit activity.
The compounds of Formula (I) may also be administered by inhalation. By "inhalation" is meant intranasal and oral inhalation administration.
Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. The daily dosage regimen for inhalation administration is suitably about .001 mg/kg to 40mg/kg, preferably 0.01 3 S to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
SUBSTITUTE SHEET (RULE 26) . Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose.
The compounds of Formula (I) may also be administered topically. By topica.l administration is meant non-systemic administration and includes the application of a compound of Formula (I) externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the I O compound does not significantly enter the blood stream. The daily dosage regimen for topical administration is suitably about .001 mg/kg to 100mg/kg, preferably 0.1 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
By systemic administration is meant oral, intravenous, intraperitoneal and I S intramuscular administration.
While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g.
from 1% to 2°o by weight ofthe formulation although it may comprise as mach as 20 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1 % to 1 % w/w of the formulation.
The topical formulations of the present invention comprise an active ingredient together with one or more acceptable carriers) therefor and optionally any other therapeutic ingredient(s). The carriers) must be'acceptable' in the sense of being 25 compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to 30 the eye, ear or nose.
Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting 35 solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100~C for half an hour.
_g_ SUBSTITUTE SHEET (RULE 26) Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. Thev may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage;
an oil of natural origin such as almond, corn, arachis, castor or olive ail; wool fat o.
its derivatives, or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or macrogols. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactants such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums. cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient, a compound of Formula (I), with which it is to be combined, the route of administration and other well-known variables.
It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration. and the particular patient being treated, and that such optimums can be determined by conventional techniques.
It will also be appreciated by one of skill in the art that the optimal course of treatment. i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable _g_ SUBSTITUTE SHEET (RULE 26) salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
FORMULATION EXAMPLES
Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients.
Examples .
of liquid formulations are given below.
1. A solution containing a compound of Formula (I) is prepared by dissolving the compound in water, or other suitable earner, with or without a preservative, such as benzoic acid, to deliver the desired amount of drug per use. The compound is present in an amount from about 10~g to about 30 fig/ per ml of carrier.
2. A solution containing a compound of Formula (I) is prepared by dissolving the compound in an amount from about 1 to about l Omg per ml of PEG 400 with or without BHA/BHT preservatives. The solution can alternatively be filled into a soft gelatin capsule to prepare a solid oral dosage form or used as a syrup.
3. A solid dosage form containing a compound of Formula (I), such as 1,3-di-cyclopropylmethyl-8-amino xanthine has been prepared by mixing SOmg of the compound with various concentration (mg) of mannitol, hydroxypropylmethylcellulose, catipharo, Starci~ 1500, and magnesium sterate (as a lubricant), to FII
CapSiiIvS cf an appropriate size or the composition may, if desired, be compressed into tablets. Various formulation of the ingredients are presented in Table 1, numbered from 1 to 6.
UTILITY EXAMPLES
The method described in the Woodward et al. manuscript, supra, served as the protoype for the mouse model which developed in the present invention. The mouse model takes advantage of the cutaneous inflammatory response to arachidonic acid which is preceeded by scratching and rubbing behavior indicative of pruritis..
Briefly. Balb/c mice were administered a topical dose of arachidonic acid (2 mg/ear) in 20 ul cold acetone to the left ear. The treated mice were then placed individually into 4L beakers. After a 2 min accommodation period, the episodes of scratching and head shaking were counted over a 10 mils period. The data were analysed by calculating the mean and standard error. A statistical difference in the mean values was determined using Student's t-test. The biochemical pharmacology of the inflammatory response to arachidonic acid has implicated mast cell degranulation and eicosanoid inflammatory mediator release (e.g. leukottienes and prostanoids).
Tachykinins and platelet activating factor may also be involved in this response. The SUBSTITUTE SHEET (RULE 26) WO 99/20280 PCT/US98/21$86 anti-inflammatory activity of phosphodiesterase type 4 (PDE4) inhibitors was also demonstrated using arachidonic acid (Griswold, D.E.et al., Pharmacology of the pyrroloimidazole, SK&F 105809. Antiinflammatory activity and inhibition of mediator production in vivo. Biochemical Pharmacology 42:825-831,1991 ) whose disclosure is incorporated by reference herein in its entirety.
Specific Methods:
Male Balb/c mice (n=6/treatrnent group) weighing 19-23 grams were administered a topical dose of arachidonic acid (2 mg/ear) in 20 ul cold acetone to the left ear.
Immediately after that application, vehicle or test compound was applied to the same ear in a volume of 25 ul. Doses varied from 5 to 1000 ug/ear. The treated mice were then placed individually into 4L beakers. After a 2 min accommodation period, the episodes of scratching and head shaking were counted over a ZO min period. The data were analysed by calculating the mean and standard error. A
statistical difference in the mean values was determined using Student's t-test.
It was of interest, therefore to determine if PDE4 inhibitors of different stmctural classes would demonstrate anti-pruritic activity in this model. As indicated below, three such PDE4 inhibitors did demonstrate signficant anti-pruritic activity.
Topical Anti-pniritic Acitivity of PDE4 Inhibitors Treatment-X100 ug/ear) __ Inhibition of Pmrids BRL 61063 61.4***
Roli ram 75.8***
CP 80633 49.7***
***, Statistically significant at a p < 0.001 versus vehicle control, BRL
61063 is the same as Compound I.
All publications, including hut not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments SUBSTITUTE SHEET (RULE 26) specifically disclosed herein are within the scope of the following claims.
Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.
SUBSTITUTE SHEET (RULE 26)
CapSiiIvS cf an appropriate size or the composition may, if desired, be compressed into tablets. Various formulation of the ingredients are presented in Table 1, numbered from 1 to 6.
UTILITY EXAMPLES
The method described in the Woodward et al. manuscript, supra, served as the protoype for the mouse model which developed in the present invention. The mouse model takes advantage of the cutaneous inflammatory response to arachidonic acid which is preceeded by scratching and rubbing behavior indicative of pruritis..
Briefly. Balb/c mice were administered a topical dose of arachidonic acid (2 mg/ear) in 20 ul cold acetone to the left ear. The treated mice were then placed individually into 4L beakers. After a 2 min accommodation period, the episodes of scratching and head shaking were counted over a 10 mils period. The data were analysed by calculating the mean and standard error. A statistical difference in the mean values was determined using Student's t-test. The biochemical pharmacology of the inflammatory response to arachidonic acid has implicated mast cell degranulation and eicosanoid inflammatory mediator release (e.g. leukottienes and prostanoids).
Tachykinins and platelet activating factor may also be involved in this response. The SUBSTITUTE SHEET (RULE 26) WO 99/20280 PCT/US98/21$86 anti-inflammatory activity of phosphodiesterase type 4 (PDE4) inhibitors was also demonstrated using arachidonic acid (Griswold, D.E.et al., Pharmacology of the pyrroloimidazole, SK&F 105809. Antiinflammatory activity and inhibition of mediator production in vivo. Biochemical Pharmacology 42:825-831,1991 ) whose disclosure is incorporated by reference herein in its entirety.
Specific Methods:
Male Balb/c mice (n=6/treatrnent group) weighing 19-23 grams were administered a topical dose of arachidonic acid (2 mg/ear) in 20 ul cold acetone to the left ear.
Immediately after that application, vehicle or test compound was applied to the same ear in a volume of 25 ul. Doses varied from 5 to 1000 ug/ear. The treated mice were then placed individually into 4L beakers. After a 2 min accommodation period, the episodes of scratching and head shaking were counted over a ZO min period. The data were analysed by calculating the mean and standard error. A
statistical difference in the mean values was determined using Student's t-test.
It was of interest, therefore to determine if PDE4 inhibitors of different stmctural classes would demonstrate anti-pruritic activity in this model. As indicated below, three such PDE4 inhibitors did demonstrate signficant anti-pruritic activity.
Topical Anti-pniritic Acitivity of PDE4 Inhibitors Treatment-X100 ug/ear) __ Inhibition of Pmrids BRL 61063 61.4***
Roli ram 75.8***
CP 80633 49.7***
***, Statistically significant at a p < 0.001 versus vehicle control, BRL
61063 is the same as Compound I.
All publications, including hut not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments SUBSTITUTE SHEET (RULE 26) specifically disclosed herein are within the scope of the following claims.
Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.
SUBSTITUTE SHEET (RULE 26)
Claims (22)
1. A method of treating pruritis in a mammal in need thereof which comprises administering to such mammal an effective amount of a compound of a PDE4 inhibitor, other than CP 80633.
2. The method according to Claim 1 wherein the PDE4 inhibitor is a compound of the formula:
wherein R1 and R2 each independently represent alkyl or -(CH2)m-A;
m represents zero or an integer 1, 2 or 3;
A represents a substituted or unsubstituted cyclic hydrocarbon radical;
R3 represents a halogen atom, a nitro group, or a group -NR4R5;
R4 and R5 each independently represent hydrogen, alkyl or alkylcarbonyl; or R4 and R5 together with the nitrogen to which they are attached form an optionally substituted heterocyclic group; and the pharmaceutically acceptable salts thereof.
wherein R1 and R2 each independently represent alkyl or -(CH2)m-A;
m represents zero or an integer 1, 2 or 3;
A represents a substituted or unsubstituted cyclic hydrocarbon radical;
R3 represents a halogen atom, a nitro group, or a group -NR4R5;
R4 and R5 each independently represent hydrogen, alkyl or alkylcarbonyl; or R4 and R5 together with the nitrogen to which they are attached form an optionally substituted heterocyclic group; and the pharmaceutically acceptable salts thereof.
3. The method according to claim 2, wherein R1 represents -(CH2)m-A.
4. The method according to claim 2, wherein R1 and R2 both independently represent -(CH2)m-A.
5. The method according to claim 4 wherein A represents a substituted or unsubstituted C3-8 cycloalkyl group.
6. The method according to claim 4, wherein m represents 1.
7. The method according to claim 6, wherein A represents a substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.
8. The method according to claim 7, wherein A represents a cyclopropyl group or a cyclobutyl group.
9. The method according to claim 8, wherein R3 is nitro, or -NR4R5 wherein R4 is hydrogen and R5 is hydrogen or alkylcarbonyl.
10. The method according to claim 9, wherein R4 or R5 is hydrogen.
11. The method according to claim 10, wherein A represents a cyclopropyl group.
12. The method according to claim 2 wherein the compound is selected from the group consisting of:
1,3-di-n-butyl-8-nitro xanthine;
1,3-di-cyclopropylmethyl-8-nitro xanthine;
1,3-di-cyclobutylmethyl-8-nitro xanthine;
1,3-di-cyclopentylmethyl-8-nitro xanthine;
1,3-di-cyclohexylmethyl-8-nitro xanthine;
1,3-di-n-butyl-8-amino xanthine;
1,3-di-cyclopropylmethyl-8-amino xanthine;
1,3-di-cyclobutylmethyl-8-amino xanthine;
1,3-di-cyclopentylmethyl-8-amino xanthine;
1,3-di-cyclohexylmethyl-8-amino xanthine;
1,3-di-cyclopropyl-8-amino xanthine;
1,3-di-n-butyl-8-acetamido xanthine;
1,3-di-n-butyl-8-chloro xanthine;
1,3-di-n-butyl-8-bromo xanthine;
1,3-di-cyclopropylmethyl-8-chloro xanthine;
1,3-di-cyclohexyl-8-chloro xanthine;
1,3-di-n-butyl-8-piperidino xanthine;
1,3-di-cyclopropylmethyl-8-morpholino xanthine;
1,3-di-n-butyl-8-pyrrolidinyl xanthine;
1,3-di-cyclopropylmethyl-8-pyrrolidinyl xanthine;
1,3-di-cyclopropylmethyl-8-piperidinyl xanthine;
1,3-di-cyclohexylmethyl-8-piperidinyl xanthine;
1,3-di-cyclohexylmethyl-8-bromo xanthine; and 1,3-di-cyclohexyl-8-nitro xanthine; or if appropriate, a pharmaceutically acceptable salt thereof.
1,3-di-n-butyl-8-nitro xanthine;
1,3-di-cyclopropylmethyl-8-nitro xanthine;
1,3-di-cyclobutylmethyl-8-nitro xanthine;
1,3-di-cyclopentylmethyl-8-nitro xanthine;
1,3-di-cyclohexylmethyl-8-nitro xanthine;
1,3-di-n-butyl-8-amino xanthine;
1,3-di-cyclopropylmethyl-8-amino xanthine;
1,3-di-cyclobutylmethyl-8-amino xanthine;
1,3-di-cyclopentylmethyl-8-amino xanthine;
1,3-di-cyclohexylmethyl-8-amino xanthine;
1,3-di-cyclopropyl-8-amino xanthine;
1,3-di-n-butyl-8-acetamido xanthine;
1,3-di-n-butyl-8-chloro xanthine;
1,3-di-n-butyl-8-bromo xanthine;
1,3-di-cyclopropylmethyl-8-chloro xanthine;
1,3-di-cyclohexyl-8-chloro xanthine;
1,3-di-n-butyl-8-piperidino xanthine;
1,3-di-cyclopropylmethyl-8-morpholino xanthine;
1,3-di-n-butyl-8-pyrrolidinyl xanthine;
1,3-di-cyclopropylmethyl-8-pyrrolidinyl xanthine;
1,3-di-cyclopropylmethyl-8-piperidinyl xanthine;
1,3-di-cyclohexylmethyl-8-piperidinyl xanthine;
1,3-di-cyclohexylmethyl-8-bromo xanthine; and 1,3-di-cyclohexyl-8-nitro xanthine; or if appropriate, a pharmaceutically acceptable salt thereof.
13. The method according to Claim 2 wherein the compound is 1,3-di-cyclopropylmethyl-8-amino xanthine or a pharmaceutically acceptable salt thereof.
14. The method of Claim 2 or 13 wherein the compound is administered orally, parenterally, topically or by inhalation.
15. The method according to Claim 14 wherein the compound is administered topically.
16. The method according to Claim 1 wherein the compound is administered topically with an effective amount of a second anti-pruritic compound.
17. The method according to Claim 1 wherein the compound is described in WO 92/00968; PCT/US91/08229; WO 92/05175; WO 92/05176; WO
92/11260; WO 93/01014; PCT/US92/03613; WO 93/07111; PCT/US93/02045;
WO 93/19748; WO 93/19750; WO 93/19751; WO 93/19747; WO 93/19749; WO
93/19720; WO 94/20079; WO 95/00139; WO 95/08581; WO 95/09308; WO
95/09623; WO 95/09836; WO 95/09624; WO 95/09837; WO 95/09627; WO
95/24381; WO 95/27692; WO 96/19995; WO 96/20158; WO 96/20153; WO
96/19980; WO 96/19988; WO 96/19977; WO 96/20161; WO 96/20157;
PCT/US95/16707; WO 96/20690; WO 96/20159; WO 96/19983; WO
96/19984; WO 96/19985; WO 96/19990; WO 96/19994; WO 96/20163; WO
96/20156; WO 96/19986; WO 96/20174; WO 96/19979; WO 96/20160 WO
96/20175; WO 96/19993; WO 96/20162; WO 96/19978; WO 96/23754; WO
96/36594;; WO 97/03945, US 5,734,051 and US 5,420,154.
92/11260; WO 93/01014; PCT/US92/03613; WO 93/07111; PCT/US93/02045;
WO 93/19748; WO 93/19750; WO 93/19751; WO 93/19747; WO 93/19749; WO
93/19720; WO 94/20079; WO 95/00139; WO 95/08581; WO 95/09308; WO
95/09623; WO 95/09836; WO 95/09624; WO 95/09837; WO 95/09627; WO
95/24381; WO 95/27692; WO 96/19995; WO 96/20158; WO 96/20153; WO
96/19980; WO 96/19988; WO 96/19977; WO 96/20161; WO 96/20157;
PCT/US95/16707; WO 96/20690; WO 96/20159; WO 96/19983; WO
96/19984; WO 96/19985; WO 96/19990; WO 96/19994; WO 96/20163; WO
96/20156; WO 96/19986; WO 96/20174; WO 96/19979; WO 96/20160 WO
96/20175; WO 96/19993; WO 96/20162; WO 96/19978; WO 96/23754; WO
96/36594;; WO 97/03945, US 5,734,051 and US 5,420,154.
18. A method of treating pruritis in a mammal in need thereof which comprises administering to such mammal an effective amount of the compound 1,3-di-cyclopropylmethyl-8-amino xanthine, or a pharmaceutically acceptable salt thereof.
19. The method of Claim 18 wherein the compound is administered orally, parenterally, topically or by inhalation.
20. The method according to Claim 19 wherein the compound is administered topically.
21. The method according to Claim 18 wherein the compound is administered topically with an effective amount of a second anti-pruritic compound.
22. The method according to Claim 21 wherein the second anti-prutitic compound is a steroid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6374697P | 1997-10-17 | 1997-10-17 | |
| US60/063,746 | 1997-10-17 | ||
| PCT/US1998/021886 WO1999020280A1 (en) | 1997-10-17 | 1998-10-16 | Novel use of compounds for anti-pruritic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2306985A1 true CA2306985A1 (en) | 1999-04-29 |
Family
ID=22051225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002306985A Abandoned CA2306985A1 (en) | 1997-10-17 | 1998-10-16 | Novel use of compounds for anti-pruritic activity |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1030666A4 (en) |
| JP (1) | JP2001520196A (en) |
| KR (1) | KR20010031149A (en) |
| CN (1) | CN1306426A (en) |
| AR (1) | AR015966A1 (en) |
| AU (1) | AU740875B2 (en) |
| BR (1) | BR9814080A (en) |
| CA (1) | CA2306985A1 (en) |
| CO (1) | CO4810374A1 (en) |
| CZ (1) | CZ20001376A3 (en) |
| HU (1) | HUP0003792A3 (en) |
| IL (1) | IL135581A0 (en) |
| NO (1) | NO20001847L (en) |
| NZ (1) | NZ503551A (en) |
| PL (1) | PL341062A1 (en) |
| TR (1) | TR200001040T2 (en) |
| WO (1) | WO1999020280A1 (en) |
| ZA (1) | ZA989450B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8492543B2 (en) | 2007-08-17 | 2013-07-23 | Eisai R&D Management Co., Ltd. | Method for producing quinazoline derivative |
| TWI404709B (en) * | 2006-02-21 | 2013-08-11 | Eisai R&D Man Co Ltd | 4-(3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives |
| US8530654B2 (en) | 2007-02-16 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL365443A1 (en) | 2001-01-31 | 2005-01-10 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
| US7250518B2 (en) | 2001-01-31 | 2007-07-31 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
| CA2436535A1 (en) | 2001-01-31 | 2002-08-08 | Prizer Products Inc. | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| WO2002060896A1 (en) | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Ether derivatives useful as inhibitors of pde4 isozymes |
| US20030175314A1 (en) * | 2001-11-19 | 2003-09-18 | Didriksen Erik Johannes | Pharmaceutical composition for dermal application |
| EP1647274A4 (en) * | 2003-07-17 | 2008-12-10 | Ono Pharmaceutical Co | Remedy for pruritus comprising piperidine derivative as the active ingredient |
| JP2005187458A (en) * | 2003-12-04 | 2005-07-14 | Santen Pharmaceut Co Ltd | Itchiness-treating agent consisting of cilomilast or its salt as active ingredient |
| WO2005053672A1 (en) * | 2003-12-04 | 2005-06-16 | Santen Pharmaceutical Co., Ltd. | Remedy for pruritus comprising cilomilast or salt thereof as the active ingredient |
| KR101100601B1 (en) * | 2004-02-14 | 2011-12-29 | 글락소스미스클라인 엘엘씨 | Novel compounds |
| JP2008137892A (en) * | 2005-03-04 | 2008-06-19 | Eisai Co Ltd | Antipruritic agent |
| JP2009504592A (en) | 2005-08-10 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | Xanthine derivatives as selective HM74A agonists |
| MX2008010774A (en) | 2006-02-21 | 2008-09-01 | Eisai R&D Man Co Ltd | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative. |
| JP5060561B2 (en) | 2007-08-17 | 2012-10-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | New topical preparation |
| EP2727594B1 (en) * | 2011-06-28 | 2017-12-20 | Mitsubishi Tanabe Pharma Corporation | Naphtalene compounds to treat itch |
| SG10201907026RA (en) | 2015-01-30 | 2019-09-27 | Shanton Pharma Co Ltd | Prevention or Treatment of Uratic or Gouty Diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992011260A1 (en) * | 1990-12-21 | 1992-07-09 | Beecham Group Plc | Xanthine derivatives |
| JP4141501B2 (en) * | 1996-03-26 | 2008-08-27 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel 6-substituted phenanthridine |
| AU2892397A (en) * | 1996-05-15 | 1997-12-05 | Byk Gulden | Novel imidazopyridines |
| PT968211E (en) * | 1997-03-07 | 2004-01-30 | Altana Pharma Ag | TETRAZOLE DERIVATIVES |
| PL336464A1 (en) * | 1997-03-18 | 2000-06-19 | Basf Ag | Method of and compositions for modulating reactivity in respect to corticosteroids i |
| JP2002502403A (en) * | 1997-06-03 | 2002-01-22 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Benzonaphthyridine |
-
1998
- 1998-10-15 AR ARP980105131A patent/AR015966A1/en not_active Application Discontinuation
- 1998-10-16 CZ CZ20001376A patent/CZ20001376A3/en unknown
- 1998-10-16 CN CN98810066A patent/CN1306426A/en active Pending
- 1998-10-16 EP EP98953608A patent/EP1030666A4/en not_active Withdrawn
- 1998-10-16 CO CO98060225A patent/CO4810374A1/en unknown
- 1998-10-16 TR TR2000/01040T patent/TR200001040T2/en unknown
- 1998-10-16 WO PCT/US1998/021886 patent/WO1999020280A1/en not_active Application Discontinuation
- 1998-10-16 NZ NZ503551A patent/NZ503551A/en unknown
- 1998-10-16 KR KR1020007004053A patent/KR20010031149A/en not_active Application Discontinuation
- 1998-10-16 BR BR9814080-9A patent/BR9814080A/en not_active IP Right Cessation
- 1998-10-16 AU AU10938/99A patent/AU740875B2/en not_active Ceased
- 1998-10-16 ZA ZA989450A patent/ZA989450B/en unknown
- 1998-10-16 HU HU0003792A patent/HUP0003792A3/en unknown
- 1998-10-16 IL IL13558198A patent/IL135581A0/en unknown
- 1998-10-16 CA CA002306985A patent/CA2306985A1/en not_active Abandoned
- 1998-10-16 JP JP2000516677A patent/JP2001520196A/en not_active Withdrawn
- 1998-10-16 PL PL98341062A patent/PL341062A1/en unknown
-
2000
- 2000-04-10 NO NO20001847A patent/NO20001847L/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI404709B (en) * | 2006-02-21 | 2013-08-11 | Eisai R&D Man Co Ltd | 4-(3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives |
| US8530654B2 (en) | 2007-02-16 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid |
| US8492543B2 (en) | 2007-08-17 | 2013-07-23 | Eisai R&D Management Co., Ltd. | Method for producing quinazoline derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| CO4810374A1 (en) | 1999-06-30 |
| BR9814080A (en) | 2000-09-26 |
| NO20001847D0 (en) | 2000-04-10 |
| CZ20001376A3 (en) | 2002-06-12 |
| AU1093899A (en) | 1999-05-10 |
| NZ503551A (en) | 2002-05-31 |
| EP1030666A1 (en) | 2000-08-30 |
| JP2001520196A (en) | 2001-10-30 |
| CN1306426A (en) | 2001-08-01 |
| NO20001847L (en) | 2000-04-10 |
| WO1999020280A1 (en) | 1999-04-29 |
| ZA989450B (en) | 1999-04-19 |
| IL135581A0 (en) | 2001-05-20 |
| TR200001040T2 (en) | 2001-01-22 |
| PL341062A1 (en) | 2001-03-26 |
| AR015966A1 (en) | 2001-05-30 |
| AU740875B2 (en) | 2001-11-15 |
| HUP0003792A3 (en) | 2001-12-28 |
| KR20010031149A (en) | 2001-04-16 |
| HUP0003792A2 (en) | 2001-10-28 |
| EP1030666A4 (en) | 2002-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU740875B2 (en) | Novel use of compounds for anti-pruritic activity | |
| Golightly et al. | Pharmaceutical excipients: adverse effects associated with inactive ingredients in drug products (Part I) | |
| JPS62249923A (en) | Drug for controlling parkinsonism, depression, narcolepsy and cerebral organ psychotic syndrome and manufacture | |
| JP2002527392A (en) | Peripherally acting antipruritic opiates | |
| ITMI20080395A1 (en) | FORMULATIONS FOR THE TREATMENT OF VARUCHE AND PSORIATIC PLATES | |
| WO2008091704A2 (en) | Treatment of cushing's syndrome and autism | |
| JPS62185014A (en) | Composite blended drug | |
| US20030050329A1 (en) | Synergistic combination comprising roflumilast and a PDE-3 inhibitor | |
| JPS625913A (en) | Dihydropyridine-containing medicine | |
| JPH02160720A (en) | Remedy composition | |
| JPH03204815A (en) | Therapeutic composition for treating dermatological disease carried by mast cell | |
| WO1999026613A1 (en) | Aminoguanidine compositions for treating skin proliferative diseases | |
| JP2016517419A (en) | Combined systemic and local treatment of damaged tissue | |
| AU3578289A (en) | Certain paf antagonist antihistamine combinations and methods | |
| JPWO2006041121A1 (en) | Treatment and / or prevention agent for chronic skin diseases | |
| JP3276762B2 (en) | Pharmaceutical composition containing isoquinoline derivative | |
| UA123780C2 (en) | Treatment of hand eczema | |
| MXPA00003775A (en) | Novel use of compounds for anti-pruritic activity | |
| JPH03215435A (en) | Ulcer treatting agent containing aldose reductase inhibitor as main ingredient | |
| JPH06500129A (en) | nucleoside derivatives | |
| JPS6245525A (en) | Hypolipemic agent | |
| US20060079513A1 (en) | Methods and compositions including methscopolamine nitrate | |
| RU2426540C1 (en) | Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition | |
| JP2503985B2 (en) | Hypnotic sedative | |
| AU1563902A (en) | Novel use of compounds for anti-pruritic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |